#WCLC21: AstraZeneca's EGFR inhibitor Tagrisso cuts relapse, death risks in patients with and without prior chemotherapy
AstraZeneca’s Tagrisso has established a strong foothold in non-small cell lung cancer — the largest section of the lung cancer community — with multiple approvals …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.